Abstract:Abstract Background Thiopurine therapy is associated with an increased risk of serious adverse events in patients with Inflammatory Bowel Disease (IBD). Thiopurine S-methyltransferase (TPMT) is the enzyme responsible for metabolism, and its determination helps identify patients at risk of toxicity. This study aims to explore the level of correspondence between the TPMT genotype and enzymatic activity (phenotype) with the objective of preventing adverse events prior to the commencement of thiopurine therapy. Methods Consecutive patients with IBD, Crohn’s Disease (CD) or Ulcerative Colitis (UC), were included. Genotype was conducted for the most prevalent TPMT variants (TPMT*2, TPMT*3B, TPMT*3C), TPMT enzymatic activity assessment, and quantification of 6-thioguanine nucleotide (6-TGN) levels. Adverse effects were documented, along with the administration of biologics, mesalazine, ACE inhibitors or allopurinol. The primary objective was to evaluate the concordance between TPMT genotype and phenotype. Secondary objectives included determining the prevalence of genotype and phenotype within our patient cohort, 6-TGN serum levels, the prevalence of adverse events and identifying potential pharmacological inducers of the phenotype. Results A total of 218 patients were included (131 with CD and 81 with UC). Thirteen patients did not initiate thiopurines, and 34.63% (71/205) had discontinued treatment. The most observed adverse events were myelotoxicity (15.12%), gastrointestinal toxicity (12.20%), and hepatic toxicity (5.37%). TPMT activity exhibited a trimodal distribution, with 87.61% (191/218) having normal activity, 11.47% having intermediate activity, and 1% having low activity. Genotypically, 90.83% (198/218) had a wild-type genotype, 8.72% (18/218) had a heterozygous genotype, and 0.5% (1/218) had a homozygous genotype. The concordance index between phenotype and genotype was calculated at 0.57. Significantly, myelotoxicity was associated with the presence of genotypic variants (p=0.004). 6-TGN levels did not correlate with TPMT activity and concurrent medications did not affect TPMT activity . Conclusion The proactive assessment of TPMT (phenotype or genotype) before initiating thiopurine therapy effectively mitigates the occurrence of myelotoxicity in IBD patients. Importantly, the level of concordance between TPMT activity and genotype is moderate, with genotyping serving as the more reliable approach for preselecting patients susceptible to myelotoxic reactions.

Significance of genetic polymorphism of the thiopurine S-methyltransferase for individualizing 6-mercaptopurine chemotherapy

Significance of TPMT activity and TGNs level detection for individualizing 6-mercaptopurine chemotherapy]

Role of TPMT Genetic Polymorphism in the Individualized Treatment of Thiopurine Drug

[The Study on Hereditary Polymorphism of Thiopurine S-methyltransferasein Chinese Han Population of Shanghai Area].

Study on the Relationship Between Genetic Polymorphism of TPMT and ITPA with Adverse Drug Reactions in 6-Mercaptopurine Treatment

[Relationship Between Single Nucleotide Polymorphisms in Thiopurine Methyltransferase Gene and Tolerance to Thiopurines in Acute Leukemia].

Thiopurine Methyltransferase Gene Polymorphisms in Chinese Patients with Inflammatory Bowel Disease

Thiopurine methyltransferase gene polymorphisms and activity in Chinese patients with inflammatory bowel disease treated with azathioprine.

P798 Study of the concordance between the enzymatic activity of Thiopurine S-methyltransferase and polymorphisms in the TPMT gene in patients with Inflammatory Bowel Disease

Molecular Diagnosis of Thiopurine S-Methyltransferase Deficiency: Genetic Basis for Azathioprine and Mercaptopurine Intolerance

[The Effect of the Adverse Events with Thiopurine S-methyltransferase Gene Mutation on Outcome of Childhood Acute Lymphoblastic Leukemia].

[Genetic Polymorphism of the Thiopurine S-methyltransferase of Healthy Han Chinese].

Determination of intra-ethnic differences in the polymorphisms of thiopurine S-methyltransferase in Chinese.

Progress in Genetic Polymorphism of Related Metabolic Enzymes Influencing Individualized Thiopurine Therapy

Analysis of Thiopurine Methyltransferase Gene Polymorphism by Denaturing HPLC

Precision therapy of 6-mercaptopurine in Chinese children with acute lymphoblastic leukaemia

Should Thiopurine Methyltransferase Genotypes and Phenotypes Be Measured Before Thiopurine Therapy in Patients with Inflammatory Bowel Disease?

Correlation between Thiopurine S-methyltransferase and Thiopurines Toxicity in Patients with Inflammatory Bowel Disease

Screening of Novel Pharmacogenetic Candidates for Mercaptopurine-Induced Toxicity in Patients With Acute Lymphoblastic Leukemia.

Thiopurine Methyltransferase Genetic Polymorphism Analysis of Azathioprine Induced Myelosuppression in SLE

Role of Thiopurine S-Methyltransferase Detection in the Treatment of Inflammatory Bowel Disease